Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?
爱美医疗爱美医疗(US:FOLD) ZACKS·2026-01-06 17:15

Key Takeaways Galafold raked in 371.5Minthefirstninemonthsof2025,accountingforover80371.5M in the first nine months of 2025, accounting for over 80% of FOLD's product sales.Galafold benefits from broad global approvals and U.S. patent protection extending through 2038.FOLD's Pombiliti Opfolda delivered 77.5M sales in the first nine months of 2025, up 61% Y/Y.Amicus Therapeutics (FOLD) has made solid progress with its lead marketed product, Galafold (migalastat), which generates the majority of the company’s revenues.Galafold is approved for treating Fabry ...